Polytherics And Viventia Sponsor ADC Summit, London 2013

Date: Apr-03-2013SMi Group are proud to announce that Polytherics, a UK Biotech company and Viventia, a Canadian biopharmaceutical company, will be sponsoring this years 2nd annual ADC Summit taking place on 20 - 21 May, London.

Polytherics partners include Spirogen, who have recently announced research collaboration with Ablynx. The new group effort will evaluate a novel anti-cancer drug conjugate combining Spirogen's cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies generated using Ablynx's technology platform. Following on from this both Spirogen and Polytherics will have a presence at the 2nd annual event.

ADC Summit will present attendees with an in-depth view into novel innovations, developments and utilities of antibody-drug conjugates that will see world-renowned expert speakers from Immunogen, UCB, Bayer, MedImmune, Spirogen and Genentec.

The conference will provide delegates with a unique insight into latest technological and scientific developments and will be the perfect platform for debate and problem-solving discussion.

Attendees will be able to:
Listen to Genentech speak on Novel Linker drugs for ADCs
See firsthand exactly where the pitfalls and advantages are of developing an anti-body drug conjugate.
Learn from expert speakers in the lead of their field from big pharma and biotech companies including Genetech, Immunogen, Spirogen and Bayer
Hear from recent advances in conjugate chemistry, target selection, novel payload deliveries, future ADC pipelines and regulatory issues.
Network at the UK's only dedicated event on ADC alongside Agensys, Celgene , Novartis, Sanofi plus many more...
For further information on the conference click here. Alternatively contact Fateja Begum on tel: +44 (0) 20 7827 6184 or email: fbegum@smi-online.co.uk.
Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.